Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages ...

A recently published study confirms what caffeine enthusiasts have suspected all along: the naturally occurring stimulant is ...

Researchers at the Francis Crick Institute have shown that the 'pacemaker' controlling yeast cell division lies inside the ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences Inc. and Kymera Therapeutics Inc. have entered into an exclusive option and license agreement.

Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Researchers at the Francis Crick Institute have shown that the "pacemaker" controlling yeast cell division lies inside the ...

Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

In diseases due to exposure to toxic particles like gout, macrophages elicit separate pathways for inflammation and lysosomal ...